Obtaining access to KIMOZO® 40 mg/ml
temozolomide oral suspension

Overview for physicians

What is KIMOZO®?

KIMOZO® 40 mg/ml is a ready-to-use and taste-masked oral suspension of temozolomide to be used for the treatment of pediatric patients aged 1 to 6 years and in patients older than 6 years who are unable to swallow temozolomide in capsule form.

KIMOZO® is presented in a kit containing 1 vial filled with 20 ml of temozolomide oral suspension and 1 dosing oral syringe graduated up to 5 ml with a 0.1 ml dosing increment.

What is KIMOZO® used for?

KIMOZO® is used for the treatment of patients diagnosed with:

- high-risk neuroblastoma after insufficient response or refractory to induction chemotherapy or with disease recurrence; and
- other indications including newly diagnosed glioblastoma multiforme as well as relapsed or refractory malignant glioma, medulloblastoma, Ewing sarcoma, rhabdomyosarcoma.

How does Named Patient Access work?

To be eligible for named patient access, a patient's physician must make a formal request on behalf of the patient to ORPHELIA Pharma. ORPHELIA Pharma will review the case and determine if KIMOZO® is an appropriate treatment for the patient.

If granted approval by ORPHELIA Pharma, the patient's physician is responsible for getting permission from their local competent authority to have KIMOZO® imported for their patient. The physician is also responsible for the patient's care and all legal and regulatory requirements for medically monitoring the patient while receiving KIMOZO®.

To date, KIMOZO® is not registered in any country of the World. ORPHELIA has partnered with Tanner Pharma Group to facilitate named patient access to KIMOZO®.

Physicians willing to prescribe KIMOZO® can contact Tanner Pharma at:

kimozo@tannerpharma.com

Tanner Pharma GROUP

ORPHELIA PHARMA

SCAN ME

KIM-2023-002-01